In the phase 2 trial, the percentage of people who reported adverse outcomes in each dose section were:

• medium dose at days 0 and 14: 6%

• alum only at days 0 and 14: 14.3%

• medium does at days 0 and 21: 19%

• alum only at days 0 and 21: 17.9%

Most common adverse reactions: injection site pain was the most common and fever was the second most common.

All adverse reactions were only reported within the first seven days of injection. (No adverse reactions reported within days 8 to 28.)